Posted by Michael Wonder on 09 Aug 2025
International study on authorisation times confirms Swissmedic's competitiveness
6 August 2025 - Latest CIRS study rates Swissmedic's authorisation procedures for human medicinal products with new active substances as internationally competitive.
The speed with which regulatory authorities are able to make scientifically sound decisions on applications for the authorisation of innovative medicines is crucially important both for the industry and for patients. At the international level, Swissmedic is keeping pace with other leading regulatory authorities.
